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human craniosynostosis, each associated with mutations within 
various growth factor signaling pathways. Knowledge gathered 
from these investigations may result in the future development 
of alternative strategies to enhance or perhaps even replace cur-
rent approaches for the treatment of craniosynostosis.
CURRENT SURGICAL TREATMENT
Craniosynostosis was first treated surgically in the late 1800s, 
using techniques such as fragmentation of the cranial vault and 
linear craniectomies. These early procedures were associated 
with high rates of reossification and poor esthetic outcomes, 
mandating many subsequent procedures7). At present, however, 
simple craniectomy is used only in patients with transient cra-
nial decompression. These early procedures have been sup-
planted by surgical remodeling of the affected area of the cranial 
vault and orbits. Surgery is generally performed at age 6–9 
months to take full advantage of the regenerative capacity of the 
skull at this age. Three stages of growth have determined the 
approach to the management of craniosynostosis3).
The early period, up to 12 months
During this time, cerebral growth is the greatest, and cranio-
synostosis may have detrimental effects on the developing brain. 
The original surgical approach consisted of excision of the pre-
mature suture or sutures by linear craniectomy, allowing the 
INTRODUCTION
Craniosynostosis is a wonderfully descriptive term, meaning 
“the skull has fused bone”. However, it is also a fairly nonspecific 
clinical designation, encompassing multiple presentations rang-
ing from isolated single suture involvement to multi-sutural fu-
sions5). Multi-sutural fusion can occur as isolated fusions or 
with associated anomalies that occur outside the skull. Epide-
miologic studies have suggested that the incidence of cranio-
synostosis may be as high as 1 in 1700 live births6,12). Several 
causes of craniosynostosis have been proposed2). For example, 
early theories regarding the pathogenesis of this condition, 
based on clinical observations and an experimental animal 
model, included intrauterine constraint8,11).
Over the last quarter century, there have been many advances 
in the understanding of craniosynostosis, resulting in more ra-
tional management of the problems associated with this condi-
tion, both in its simple form and its syndromic manifesta-
tions3,15). These advances have included reduced emphasis on 
the technical aspects of this disease and greater emphasis on its 
pathology and natural history, along with more accurate analy-
sis of the morphology of the craniofacial skeleton1,3,10). More re-
cently, genetic studies have identified the genetic loci of many 
craniosynostosis syndromes, as well has determining the down-
stream pathways associated with disease development. Recent 
clinical and genetic studies have identified multiple forms of 
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FUTURE PERSPECTIVES IN CRANIOSYNOSTOSIS
The combination of early technical success with recent ad-
vances in treatment14) has indicated the necessity of multidisci-
plinary management. The overall approach can be distilled into 
six principles9) : 1) Care should be provided by multi-disciplin-
ary teams; 2) Care should be a protocol-driven process, with all 
forms of care defined and delivered optimally; 3) Care should 
be longitudinal, as age, healing and growth processes; 4) Secure 
financial support is needed to implement such longitudinal 
care11); 5) Competent professionals should be involved in ongo-
ing education and training in teaching and research; and 6) Re-
search should explore causes, treatment strategies, and treat-
ment outcomes.
CONCLUSION
Centers with the appropriate vision and infrastructure are 
necessary to optimize the care of patients with craniosynostosis, 
as well as to enhance scientific knowledge and education about 
this disease. Several investigations have evaluated the roles of 
various growth factors and cytokines in determining the fate of 
sutures. Fibroblast growth factors (FGFs) are particularly im-
portant, as mutations in their receptors have been implicated in 
many craniosynostosis syndromes. Mutations in three of the 
four known FGF receptors have been associated with prema-
ture pathologic suture fusions16,17). Recent advances in develop-
mental biology and genetics have identified some of the events 
governing suture fate, highlighting multiple axes of cellular sig-
naling with the potential for clinical manipulation. Such knowl-
edge and comprehension may facilitate therapeutic translations, 
ultimately enhancing or perhaps even replacing contemporary 
modalities for treating craniosynostosis.
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